EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

O ‐GlcNAc Transferase Promotes Metabolic Dysfunction‐Associated Steatotic Liver Disease‐Related Hepatocellular Carcinoma by Facilitating the Degradation of PTEN

Haoran Liu, Suming Pu, Wenxin Zhu, Jing Huang, Jianming Li

MedComm – Oncology · 2025-12 · 4 (4)

DOI: 10.1002/mog2.70042 ↗

Kurz gefasst

Fachartikel in der Zeitschrift MedComm – Oncology, online erschienen am 14.10.2025. Verfasst von Haoran Liu und 4 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction‐associated steatotic liver disease (MASLD) is a major risk factor for hepatocellular carcinoma (HCC), yet treatment options for advanced disease remain limited. O ‐GlcNAc transferase (OGT), the enzyme catalyzing O ‐GlcNAcylation, has been implicated in tumorigenesis, but its pro‐cancer mechanism in MASLD‐HCC remains poorly defined. Here, we show that OGT expression is significantly upregulated during MASLD‐HCC progression and negatively regulates the tumor suppressor phosphatase and tensin homolog deleted on chromosome ten (PTEN) both in vivo and in vitro . Mechanistically, OGT catalyzes O ‐GlcNAcylation of PTEN at T382, which competitively inhibits the phosphorylation at the same residue. This modification promotes PTEN ubiquitination and accelerates its degradation. Importantly, O ‐GlcNAcylation of PTEN simultaneously impairs its intrinsic phospholipase activity. These dual effects compromise PTEN function, leading to activation of PI3K/Akt signaling pathway and enhanced tumor cell proliferation and migration. Moreover, pharmacological inhibition of OGT suppresses tumor growth and, when combined with PI3K/Akt pathway inhibitors, produces additive antitumor effects. These findings reveal a novel mechanism by which OGT‐mediated O ‐GlcNAcylation destabilizes and inactivates PTEN, driving MASLD‐HCC progression. They also highlight OGT and PTEN as promising therapeutic targets for developing novel strategies against HCC.

Zitieren

APA

Liu, H., Pu, S., Zhu, W., Huang, J., & Li, J. (2025). O ‐GlcNAc Transferase Promotes Metabolic Dysfunction‐Associated Steatotic Liver Disease‐Related Hepatocellular Carcinoma by Facilitating the Degradation of PTEN. MedComm – Oncology, 4(4). https://doi.org/10.1002/mog2.70042

Vancouver

Liu H, Pu S, Zhu W, Huang J, Li J. O ‐GlcNAc Transferase Promotes Metabolic Dysfunction‐Associated Steatotic Liver Disease‐Related Hepatocellular Carcinoma by Facilitating the Degradation of PTEN. MedComm – Oncology. 2025;4(4). doi:10.1002/mog2.70042

BibTeX
@article{Liu2025,
  author = {Liu, Haoran and Pu, Suming and Zhu, Wenxin and Huang, Jing and Li, Jianming},
  title = {O ‐GlcNAc Transferase Promotes Metabolic Dysfunction‐Associated Steatotic Liver Disease‐Related Hepatocellular Carcinoma by Facilitating the Degradation of PTEN},
  journal = {MedComm – Oncology},
  year = {2025},
  volume = {4},
  number = {4},
  doi = {10.1002/mog2.70042}
}
Kostenlos starten →